Compare GRWG & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRWG | ANIX |
|---|---|---|
| Founded | 2008 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.7M | 100.6M |
| IPO Year | 2015 | 2013 |
| Metric | GRWG | ANIX |
|---|---|---|
| Price | $1.78 | $2.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 694.7K | 103.8K |
| Earning Date | 05-08-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.22 | 12.82 |
| EPS | N/A | N/A |
| Revenue | ★ $193,365,479.00 | $210,000.00 |
| Revenue This Year | $5.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 142.51 | N/A |
| 52 Week Low | $0.93 | $2.44 |
| 52 Week High | $2.40 | $5.46 |
| Indicator | GRWG | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 71.27 | 43.67 |
| Support Level | $1.44 | $2.44 |
| Resistance Level | $1.82 | $3.12 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 85.09 | 32.65 |
GrowGeneration Corp owns and operates specialty retail stores focused on hydroponic and organic gardening. The company markets and distributes nutrients, growing media, indoor and greenhouse lighting, ventilation systems, and related accessories. It operates through two reportable segments: Cultivation and Gardening, which includes its hydroponic and organic gardening business, and Storage Solutions, which includes its benching, racking, and storage solutions operations. The company generates revenue mainly from the sale of proprietary and non-proprietary products through retail stores, e-commerce platforms, wholesale distribution, and commercial sales, along with the sale and installation of commercial fixtures.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.